Please Wait.....
Report
Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Market Report (15 days) I 2024-04-23 I 214 Pages I IMARC Group
The 7 major multiple myeloma markets reached a value of US$ 16.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 38.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8% during 2024-2034.
The multiple myeloma market has been comprehensively analyzed in IMARC's new report titled "Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Multiple myeloma is a cancer of the plasma cells. Plasma cells are white blood cells that make antibodies which protect against infection. Multiple myeloma involves an excessive growth of the cells crowding out normal cells in the bone marrow that produce red blood cells, platelets, and other white blood cells. Early on, patients having multiple myeloma might not notice any symptoms. But over time, they may develop common symptoms which include bone pain, weakness and fatigue, weight loss and loss of appetite, stomach problems, confusion, frequent infections, severe thirst, weakness or numbness in arms and legs, etc. Multiple myeloma can be hard to diagnose as it usually has few or no symptoms in the initial stages. Diagnosis for multiple myeloma may involve a range of blood tests, urine tests and bone or bone marrow tests. A number of these tests may also be used to assess the extent of the disease and to plan and monitor treatment.
One of the biggest drivers of the multiple myeloma market is the rising geriatric population. Since the incidence of multiple myeloma increases with age and rarely happens in people younger than 45 years of age, we expect a continuous growth in the global ageing population to create a positive impact on the multiple myeloma market. Furthermore, a rising prevalence of physical inactivity, overweight, obesity, and diabetes are also expected to drive this market as these factors are also associated with an increasing incidence and mortality of this indication. Multiple myeloma is now treated like a chronic disorder catalyzed by the rising efficiency and safety of currently available treatments. The cost of therapy for multiple myeloma, however, has become increasingly high as patients are living longer and use these treatments for extended periods of time. This cost burden on both payers and providers, however, will get some relief once generic versions for some of the key drugs are launched across the major markets.
IMARC Group's new report provides an exhaustive analysis of the multiple myeloma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple myeloma market in any manner
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the multiple myeloma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the multiple myeloma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current multiple myeloma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the multiple myeloma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the multiple myeloma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the multiple myeloma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the multiple myeloma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of multiple myeloma?
What will be the growth rate of patients across the seven major markets?
Multiple Myeloma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for multiple myeloma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple myeloma market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Multiple Myeloma - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 Multiple Myeloma - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Multiple Myeloma - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 Multiple Myeloma - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Multiple Myeloma - Unmet Needs
10 Multiple Myeloma - Key Endpoints of Treatment
11 Multiple Myeloma - Marketed Products
11.1 List of Multiple Myeloma Marketed Drugs Across the Top 7 Markets
11.1.1 Revlimid (Lenalidomide) - Celgene
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Sarclisa (Isatuximab) - Sanofi
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Xpovio (Selinexor) - Karyopharm
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Empliciti (Elotuzumab) - Bristol Myers Squibb/AbbVie
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 Multiple Myeloma - Pipeline Drugs
12.1 List of Multiple Myeloma Pipeline Drugs Across the Top 7 Markets
12.1.1 Binimetinib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Elranatamab - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Iberdomide - Celgene, Bristol-Myers Squibb
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Masitinib - AB Science
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. Multiple Myeloma - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Multiple Myeloma - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Multiple Myeloma - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Multiple Myeloma - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Multiple Myeloma - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Multiple Myeloma - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Multiple Myeloma - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Multiple Myeloma - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Multiple Myeloma - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Multiple Myeloma - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Multiple Myeloma - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Multiple Myeloma - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Multiple Myeloma - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Multiple Myeloma - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Multiple Myeloma - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Multiple Myeloma - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Multiple Myeloma - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Multiple Myeloma - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Multiple Myeloma - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Multiple Myeloma - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Multiple Myeloma - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Multiple Myeloma - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Multiple Myeloma - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Multiple Myeloma - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Multiple Myeloma - Access and Reimbursement Overview
15 Multiple Myeloma - Recent Events and Inputs From Key Opinion Leaders
16 Multiple Myeloma Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 Appendix
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security